Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.